RADIANT-4: Results of international trial show promise in the treatment of neuroendocrine tumours

1 Views

07/09/23

Prof Yao presents the results of his study which has shown that the mTOR inhibitor, everolimus, can delay tumour growth among both gastrointestinal and lung NETs, at a press conference at ECC 2015.

The results of this phase III study have shown that the mTOR inhibitor everolimus can delay tumour growth among patients with both advanced, progressive, non-functional gastrointestinal (GI) and lung neuroendocrine tumours (NETs).

Around 75% of NETS are non-functional meaning that they do not produce any specific hormones and the population of patients with non-functional GI and lung NETS has a limited number of treatment options.
Indeed, no other agents have been approved or have shown any significant efficacy in these tumours before everolimus in the RADIANT-4 study.